Genetically modified tumor-targeted bacteria with reduced virulence
United States Patent 6,080,849
Bermudes , et al. June 27, 2000
Abstract
The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
--------------------------------------------------------------------------------
Inventors: Bermudes; David (Wallingford, CT); Low; Kenneth Brooks (Guilford, CT)
Assignee: Vion Pharmaceuticals, Inc. (New Haven, CT); Yale University (New Haven, CT)
Appl. No.: 926636
Filed: September 10, 1997
snip....
--------------------------------------------------------------------------------
Processes for high-yield diastereoselective synthesis of dideoxynucleosides
United States Patent 6,005,097
Chen , et al. December 21, 1999
Abstract
The present invention relates to methods for substantially enhancing the stereoselective synthesis of .beta.-anomeric nucleoside analogs. In methods according to the present invention, the introduction of a phenylseleno group onto a blocked lactone sugar precursor may be selected so that the desirable phenylseleno substituent is introduced on the side of the blocked lactone away from the blocking group. This stereospecific introduction of the phenylseleno group in sugar precursor allows the synthesis of nucleoside analogs and in particular, 2',3',-dideoxy- and 2',3'-dideoxy-2',3'-didehydronucleoside analogs in very high yield. In certain preferred embodiments, the preferred phenylseleno blocked lactone is obtained in an amount representing approximately 90% or more of the total amount of the stereoisomers obtained. In even more preferred embodiments, the amount of the preferred stereoisomer is at least 95%, even more preferably at least about 97% of the total amount of phenylseleno blocked lactone produced.
--------------------------------------------------------------------------------
Inventors: Chen; Shu-Hui (Hamden, CT); Li; Xiuyan (New Haven, CT)
Assignee: Vion Pharmaceuticals, Inc. (New Haven, CT)
Appl. No.: 663674
Filed: June 14, 1996
snip....
--------------------------------------------------------------------------------
Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP
United States Patent 5,869,676
Niu , et al. February 9, 1999
Abstract
The present invention relates to improved, efficient chemical syntheses of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP).
--------------------------------------------------------------------------------
Inventors: Niu; ChuanSheng (Cheshire, CT); Li; Jun (Hamden, CT); Li; Xiuyan (New Haven, CT); Doyle; Terrence W. (Killingworth, CT); Chen; Shu-Hui (Hamden, CT)
Assignee: Vion Pharmaceuticals, Inc. (New Haven, CT)
Appl. No.: 856559
Filed: May 15, 1997 |
